Clinical Scenario:
A 12-year-old boy presents with progressive difficulty in school performance, personality changes, and intermittent tremors for the past 6 months. Examination reveals dysarthria, dystonia, and abnormal involuntary movements. Slit-lamp examination shows a brownish ring at the corneal margin. Liver function tests are mildly abnormal, and serum investigations reveal low ceruloplasmin levels with increased urinary copper excretion. Which of the following is the most appropriate initial treatment?
A) Levodopa therapy
B) Oral copper chelation therapy
C) Pyridoxine supplementation
D) Sodium benzoate therapy
E) Valproate therapy
Correct answer & Explanation:
Correct Answer: B) Oral copper chelation therapy
Explanation: Wilson Disease
This patient has Wilson disease, an autosomal recessive disorder of copper metabolism caused by pathogenic variants in the ATP7B gene. The ATP7B protein is essential for incorporating copper into ceruloplasmin and excreting excess copper into bile. Defective copper transport leads to progressive accumulation of copper, particularly in the liver, brain, and cornea.
Wilson disease commonly presents during childhood or adolescence with hepatic, neurological, psychiatric, or ophthalmological manifestations.
The clinical features in this case are characteristic:
Neurological manifestations: Tremor, dystonia, dysarthria, and other movement disorders due to copper deposition in the basal ganglia.
Psychiatric manifestations: Personality changes, irritability, depression, behavioral disturbances, or declining academic performance.
Kayser–Fleischer rings: Brownish or greenish copper deposition at the peripheral cornea, best visualized by slit-lamp examination.
Low serum ceruloplasmin: Reduced ceruloplasmin is a common finding, although it is not diagnostic on its own.
Increased urinary copper excretion: Reflects abnormal copper accumulation and is an important diagnostic finding.
Why Option B is correct: Oral copper chelation therapy
The initial treatment of symptomatic Wilson disease generally involves a copper-chelating agent, such as D-penicillamine or trientine. These drugs bind excess copper and promote its excretion in the urine, thereby reducing copper accumulation in tissues.
Chelation therapy is particularly appropriate in patients with neurological manifestations or significant hepatic disease requiring active copper removal.
Treatment is usually continued lifelong. Once copper levels are controlled, therapy may be adjusted according to the patient’s clinical status and response.
Zinc therapy is another treatment option. Zinc reduces intestinal copper absorption by inducing metallothionein in enterocytes, which binds dietary copper and limits its entry into the circulation. It may be used in selected patients, including some patients receiving maintenance therapy, but it is not a substitute for urgent copper removal in patients who require chelation.
Why the other options are incorrect
A) Levodopa therapy — Incorrect
Levodopa is used primarily to treat Parkinsonian symptoms by increasing dopamine availability in the brain. Although Wilson disease may cause movement disorders, levodopa does not correct the underlying copper accumulation and is not a disease-modifying treatment for Wilson disease.
C) Pyridoxine supplementation — Incorrect
Pyridoxine, or vitamin B6, is used in selected metabolic and neurological conditions, including pyridoxine-dependent epilepsy. It does not remove excess copper or treat the underlying defect in Wilson disease.
D) Sodium benzoate therapy — Incorrect
Sodium benzoate is used in the management of certain urea cycle disorders and other causes of hyperammonemia. It promotes nitrogen excretion but has no role in removing excess copper in Wilson disease.
E) Valproate therapy — Incorrect
Valproate is an antiseizure medication used for selected seizure disorders. It does not treat copper accumulation and may cause hepatotoxicity. It should therefore be used cautiously, or avoided when appropriate, in patients with significant liver disease.
Exam Pearl
Child or adolescent with movement disorders, behavioral changes, and Kayser–Fleischer rings → think Wilson disease.
In symptomatic Wilson disease, treatment generally requires active copper removal with penicillamine or trientine. Zinc reduces intestinal copper absorption and may be used in selected treatment strategies.
Reference
Roberts EA, Schilsky ML. Diagnosis and treatment of Wilson disease: an update. Hepatology. 2008;47(6):2089–2111.
Wilson Disease. GeneReviews®. NCBI Bookshelf. Read the full clinical review.
You can also practice more MCQs on CNS.
